COVID-19 is an infectious disease caused by SARS-CoV-2 leading to the ongoing global
pandemic. Infected patients developed a range of respiratory symptoms, including …

The continued emergence of highly pathogenic viruses, which either thwart immune-and
small molecule-based therapies or lack interventions entirely, mandates alternative …

From the (patho) physiological point of view, diseases can be considered as emergent
properties of living systems stemming from the complexity of these systems. Complex …

Identifying novel drug-target interactions is a critical and rate-limiting step in drug discovery.
While deep learning models have been proposed to accelerate the identification process …

Massive efforts on both vaccine development and antiviral research were launched to
combat the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …

Drugs against novel targets are needed to treat COVID-19 patients, especially as SARS-
CoV-2 is capable of rapid mutation. Structure-based de novo drug design and repurposing …

High drug development costs and the limited number of new annual drug approvals
increase the need for innovative approaches for drug effect prediction. Severe acute …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hijacks multiple human
proteins during infection and viral replication. To examine whether any viral proteins employ …

Abstract Coronavirus disease 2019 (COVID‐19) is an infectious disease caused by severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which led to the current …

We and others have approached this problem through the lens of molecular interaction
networks (Figure 1). Molecular networks (eg, protein-protein interaction networks, metabolic …